CARSON CITY, Nevada, December 9, 2021 / PRNewswire / – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), today released a second CEO Leadership Update Peter Wojcik. Today’s update provides more information on the company’s strategy to convert the revenue potential of its proprietary intellectual property into realized revenue. The first update can be viewed and the following link:
Pharmagreen Harnesses the Revenue Potential of Proprietary Cannabis Tissue Culture Technology Asset
Today’s update is included in full below:
Strategic update from CEO Peter Wojcik
The transition of Pharmagreen’s revenue potential derived from its proven intellectual property asset will rest on the foundation of leadership talents who have converged at Pharmagreen to transform the cannabis industry by making Pharmagreen proprietary tissue culture the standard of the industry. industry for industrial cultivation operations.
Pharmagreen has a proprietary tissue culture process called “Chibafreen” which can be applied to the cannabis industry to increase the scalability of industrial cultivation operations while maintaining genetic purity and improving quality production.
Check out my update posted last week to learn more about our proprietary Chibafreen process.
As CEO of Pharmagreen, I approach the cannabis industry with Chibafreen as an agent of economic change for the cannabis industry. Yes, Chibafreen is a differentiator for Pharmagreen as a proprietary technology, but its value will be realized and monetized through its potential to positively impact the economy of the cannabis industry with improved efficiency. can offer.
I bring to Pharmagreen a solid history of knowledge and experience in economics which I have used to develop a solid business strategy for Pharmagreen. I am a University of Regina alum, and I bring invaluable experience with a number of high-value existing alumni built from startups. My professional experience also includes extensive research on cannabis as a therapeutic agent.
Pharmagreen has absolutely the best COO in place to handle our plant tissue culture differentiation exclusive to Chibafreen. Dr Fawzia Afreen’s extraordinary career spans almost two decades as an expert in plant horticulture, tissue culture and production. In addition to his doctorate. in botany from the University of Hull in the UK, she holds three international patents, two published books and more than forty articles used in international peer-reviewed journals.
As a high-growth public company, the role of the CFO is essential in structuring and managing the company’s financial strategy to support our goals of rapid expansion. Terry kwan is a Chartered Professional Accountant with the Institute of Chartered Professional Accounts of British Columbia. that of Terry Kwan a four-decade career portfolio in finance spans both the public and private sectors. The University of British Columbia alum has the commercial expertise to analyze our financial expenses and our profitability.
I have no doubts that Pharmagreen has the right leadership team in place to serve as the basis for the company’s strategy to evolve the economics of the cannabis industry through industry-wide adoption of the Pharmagreen’s proprietary Chibafreen plant tissue culture process.
As we continue to transform the revenue potential of Pharmagreen’s proprietary technology into realized revenue, the company will continue to issue a series of letters to shareholders building on the first and today to articulate the details in plain and simple terms. of every key aspect of the overall strategy to turn Chibafreen’s assets into a source of recurring revenue.
Look for the next episode which will be released next week.
Please visit update.pharmagreen.ca for more information on the current business development of PHBI.
About Pharmagreen Biotech Inc.
Pharmagreen Biotech, Inc., is a publicly traded company (OTC PINKS: PHBI). Pharmagreen Biotech Inc. is engaged in providing the highest quality starter seedlings using a proprietary tissue culture process, “Chibafreen”, to licensed cannabis growers and CBD / CBG hemp growers. It also provides other value-added services: identification of plant species through DNA testing and certification; live storage of all plant strains using tissue culture and proprietary low temperature storage technology. Using the finest tissue culture seedlings in its state-of-the-art greenhouses for the production of the highest quality flowering tops. For more information about the company, please visit www.pharmagreen.ca
Safe Harbor Declaration
This press release contains forward-looking statements. These forward-looking statements are subject to a number of risks, assumptions and uncertainties which could cause the actual results of the Company to differ materially from those projected in these forward-looking statements. In particular, factors that could cause actual results to differ materially from forward-looking statements include: our inability to obtain additional financing on acceptable terms; the risk that our products and services will not be widely accepted by the market; the inability to compete with others who provide comparable products; the failure of our technology; infringement of our technology with the proprietary rights of third parties; inability to meet consumer demands; the inability to replace major clients; seasonality of our activity. Forward-looking statements speak only as of the date of their publication and are not guarantees of future performance. We assume no obligation to publicly update or revise any forward-looking statements. When used in this document, the words “believe”, “expect”, “anticipate”, “estimate”, “project”, “plan”, “should”, “intend”, ” could ”,,“ “potential” and similar expressions may be used to identify forward-looking statements.
OTC Markets or any other securities regulatory authority has not reviewed and accepts no responsibility for the adequacy or accuracy of this press release which has been prepared by management.
Phone. : (702) 803 9404
SOURCE Pharmagreen Biotech, Inc.